Abstracts tagged "T Cell"

Abstract Number: 0904 • ACR Convergence 2024
Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing
Yuriy Baglaenko¹, MIchelle Curtis², Majd Al Suqri³, Ryan Agnew³, Aparna Nathan⁴, Hafsa Mire⁴, Annelise Yoo Mah-Som³, David Liu⁵, Gregory Newby⁶ and Soumya Raychaudhuri³, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Broad Institute, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, MA, ⁵Broad Institute, Cambridge, MA, ⁶Johns Hopkins, Baltimore, MD
Background/Purpose: Genetic studies have identified thousands of individual disease-associated non-coding alleles, but identification of the causal alleles and their functions remain critical bottlenecks. Even though…
Abstract Number: 1755 • ACR Convergence 2024
Single Cell TCR Sequencing Suggests Potential Limitations of TRBV9-depleting Therapies in Axial Spondyloarthritis
Michael Paley¹, Xinbo Yang², Lynn Hassman¹, Grace Paley¹, Nicole Linskey¹, Ryan Agnew¹, Paulo Arantes de Faria¹, Annie Feng¹, Sophia Li¹, Elisha Roberson¹, Philip Ruzycki¹, Ekaterina Esaulova¹, Jennifer Laurent¹, Lacey Feigl¹, Luke Springer¹, Chang Liu¹, K. Chris Garcia³ and Wayne Yokoyama⁴, ¹Washington University in St. Louis, Saint Louis, MO, ²Sloan Kettering Institute, New York, NY, ³Stanford, Stanford, CA, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: TRBV9 depletion is a novel strategy for the treatment of HLA-B27+ axial spondyloarthritis (axSpA) and has achieved clinical remission in at least one patient.…
Abstract Number: 1844 • ACR Convergence 2024
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
Ethan BenDavid, Nathanael Joshua Bangayan, Orit Foord, Michael Weist, Melanie Munguia, Jessica Reyes and Jiajia Cui, ImmPACT Bio, West Hills, CA
Background/Purpose: Immunotherapies targeting antigens expressed on B cells are currently being explored as treatments for autoimmune disorders like antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic…
Abstract Number: 1863 • ACR Convergence 2024
Human Endogenous Retroviruses Promote the Aberrant T Cell Differentiation in Systemic Lupus Erythematosus
Xiaoli Min¹, Jiali Wu², Yaqin Yu³, Qianjin Lu⁴ and Ming Zhao⁴, ¹Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China (People's Republic), ²Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³Central South University, Changsha, China (People's Republic), ⁴Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic)
Background/Purpose: Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs and systems. The complex pathogenesis of SLE involved the abnormal activation of CD4+T cells and DNA hypomethylation modification. Human endogenous retroviruses (HERVs)…
Abstract Number: 2598 • ACR Convergence 2024
p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA
Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
Abstract Number: 0096 • ACR Convergence 2024
Simultaneous Contribution of Brain-Intrinsic and Peripheral Disease Mechanisms to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus (NPSLE)
Hadijat Makinde¹, Mohammad Khan¹, Cecilia Stumpf², Yidan Wang³, Tyler Therron², Margaret Goldman², Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Hanover Park, IL, ⁴Northwestern University, Skokie, IL
Background/Purpose: While NPSLE are among the least understood complications, increasing evidence points to microglia, a brain-resident innate immune cell population, as a driver of disease.…
Abstract Number: 0922 • ACR Convergence 2024
Generation and Pathophysiological Analysis of M694I Variant Knock-in Mice of Human MEFV Gene: Insights from Single-Cell RNA Sequencing
Tomohiro Koga, Yoshika Tsuji and Atsushi Kawakami, Nagasaki University, Nagasaki, Japan
Background/Purpose: The primary objective of this study was to generate knock-in mice with the M694I variant of the human MEFV gene, a critical variant in…
Abstract Number: 1768 • ACR Convergence 2024
A Potential Role of Longstanding IL-18 Stimulation in the Susceptibility for Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Greta Rogani¹, Remco Erkens¹, Marein Putmans¹, Rianne Scholman¹, Jorg van Loosdregt² and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Macrophage Activation Syndrome (MAS) is a pathologic condition of immune hyperactivation, which occurs in 10-30% of cases of Still’s Disease (SD), the spectrum of…
Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1864 • ACR Convergence 2024
S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Julia Manasson¹, Marisella Panduro², Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Chapel Hill, NC
Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…
Abstract Number: 2632 • ACR Convergence 2024
Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren’s Disease
Zhi Feng sherman Lim¹, Yi Tian Ting¹, Fabien Vincent², Maureen Rischmueller³, Eric Morand⁴ and Joshua Ooi¹, ¹Monash University-T Cell Therapies Research Group, Clayton, Victoria, Australia, ²Monash University, Clayton, Victoria, Australia, ³RheumatologySA, Adelaide, Australia, ⁴School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Autoantigen-specific regulatory T cells (Tregs) are potent, and specific, suppressors of pathogenic autoimmunity, and can be harnessed to treat autoimmune disease. In primary Sjögren’s…
Abstract Number: 0246 • ACR Convergence 2024
Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies
Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
Abstract Number: 0943 • ACR Convergence 2024
Cytosporone B, a Selective Agonist of Nr4a1, Inhibits Th17 Differentiation and Alleviates Experimental Arthritis in SKG Mice
Yoichi Nakayama¹, Ryosuke Hiwa², Ayaka Okubo¹, Mikihito Shoji³, Mirei Shirakashi⁴, Hideaki Tsuji², Koji Kitagori⁵, Ran Nakashima², Shuji Akizuki⁶, Hajime Yoshifuji² and Akio Morinobu⁷, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³[email protected], Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁵Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: NR4A family regulates T cell tolerance mechanisms, including thymic-negative selection, Treg generation and function, and anergy/exhaustion. Among the three NR4A nuclear receptors, Nur77, the…
Abstract Number: 1772 • ACR Convergence 2024
Modeling and Predicting HLH Through Measurement of Immune Synapse Duration, Cytokine Production, and Target Cell Death
Anastasia Frank-Kamenetskii¹, Jemy Varghese², Jeremy Morrissette³, Hannah Klinghoffer⁴, Caroline Diorio⁵, Janis Burkhardt⁶ and Scott Canna², ¹CHOP/UPENN, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania - Perelman School of Medicine, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁶The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Hyperinflammation is a life-threatening systemic inflammatory state most commonly associated with Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS), but observed in nearly all inflammatory…
Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Amy Anderson¹, Henrique de Paula Lemos¹, Hendrik Nel², Sofia Sorbet Santiago¹, Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville⁴, Stefan Siebert⁴, Iain McInnes⁵, Carl Goodyear⁴, Catharien Hilkens¹, Andrew Filer⁶, Karim Raza⁶, Christopher Buckley⁷, Hugh Reid⁸, Kenneth Baker¹, Arthur Pratt³, Jamie Rossjohn⁸, Ranjeny Thomas⁹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁶Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].